The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

COVID-19 Clinical Trial

Official title:

A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04659239
• Other study ID #: 20200404
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: January 28, 2021
• Est. completion date: July 2022

Study information

• Verified date: February 2021
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.

Description:

The trial includes two parts, namely the efficacy study and immunogenicity bridging study. A total of 34020 participants will be enrolled, i.e. 32820 for efficacy cohort, and 1200 for domestic immunogenicity cohort in China.

Efficacy study: Participants will be randomly inoculated with two doses of investigational vaccine or placebo according to 1:1 ratio following Day 0-Day 14 immunization schedule and will be observed from the first dose of investigational vaccine to collect symptomatic and laboratory-confirmed COVID-19 cases for the evaluation of the efficacy of the investigational vaccine.

Immunogenicity bridging study: Before inoculating the first dose, 14 days, 6 months and 12 months after the whole-course immunization, blood samples will be taken for determination of neutralizing antibody and IgG antibody against SARS-CoV-2 (ELISA method); and before inoculating the first dose, 6 months and 12 months after the whole-course immunization, blood samples will be taken for detecting specific T cells with the ELISPOT assay with an aim to evaluate immunogenicity and immune persistence.

Safety observations for all participants will be conducted from the first dose to 28 days after the whole-course immunization, and follow-up of SAEs will also be conducted from the first dose to at least 12 months after the whole-course immunization to evaluate the safety of the investigational vaccine.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 34020
• Est. completion date: July 2022
• Est. primary completion date: September 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults aged 18 years and above (including boundary values), both female and male.

2. Legal identification of the participants shall be provided.

3. Participants shall understand the content in the Informed Consent Form (ICF) and the vaccine for administration, sign the ICF voluntarily and are capable of using thermometers and rulers, and filling in diary cards and contact cards as per the requirements.

4. Subject shall be able to communicate well with investigators, understand and comply with the requirements of this study.

5. Participants with oral temperature = 37.9 ?.

6. Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive OR consistently use any of the following methods of contraception:

1. Condoms (male or female)

2. Diaphragm with spermicide

3. Cervical cap with spermicide

4. Intrauterine device

5. Oral or patch contraceptives

6. Any country regulatory-approved contraceptive method that is designed to protect against pregnancy

7. Abstinence, as a form of contraception, is acceptable if in line with the participant's lifestyle (other approaches to abstinence are not acceptable).

Exclusion Criteria:

1. Contraindications to commonly used vaccines;

2. History of allergy to any vaccines or drug;

3. Received any vaccine within 1 month before the first dose of vaccination;

4. Serious diseases required to be excluded, including but not limited to history of diseases in nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other systems, and a history of malignant tumors;

5. Before immunizing the first dose of investigational vaccine, those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days;

6. Those who have a hereditary bleeding tendency or blood coagulation dysfunction, or a history of thrombosis or hemorrhagic disease;

7. Surgical removal of whole or part of spleen for any reason;

8. Those who have undergone surgery within 3 months before signing the ICF or those who plan to undergo surgery during or within 3 months after completion of the trial (including plastic surgery, dental and oral surgery);

9. Those who donated or lost blood (=400 mL) in the past 3 months, who received blood transfusion or use of blood products, or who plan blood donation during the trial;

10. Those who received other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months before signing the ICF, or plan to use them during the study.

11. Those who received immunosuppressant therapy within 6 months before signing the ICF, such as long-term systemic glucocorticoid treatment (with systemic glucocorticoid therapy for more than 2 consecutive weeks within 6 months, such as prednisone or similar drugs), but local administration is permitted (such as ointment, eye drops, inhalants, or nasal spray). The local administration should not exceed the recommended dose in the package insert or have any signs of systemic exposure;

12. Participants cannot meet the criteria through the comprehensive physical examination, mainly including:

• Abnormal vital signs with clinical significance (awakening heart rate <55 beats/min or >100 beats/min, systolic blood pressure =140mmHg or diastolic blood pressure =90mmHg);

• Those who tested positive for type 1 or type 2 human immunodeficiency virus (HIV-1/2) antibody, or SARS-CoV-2 nucleic acid;

13. History of COVID-19;

14. Participants who have a positive pregnancy test, or are breastfeeding, or planning pregnancy, or plan to donate sperm or eggs within 12 months from the screening period to the whole-course immunization;

15. Participants who are considered as inappropriate for the trial by investigators.

16. Suspected or known current alcohol or drug dependency.

17. Investigator site personnel directly related to this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• Inactivated SARS-CoV-2 Vaccine (Vero cell)
The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
• Placebo
The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

Locations

Country	Name	City	State
Brazil	CEMEC Pesquisa Clinica	São Bernardo do Campo	São Paulo
Malaysia	Hospital Sungai Buloh	Sungai Buloh	Selangor

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Countries where clinical trial is conducted

Brazil,  Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The surrogate endpoint of immunogenicity	The correlation between the efficacy of the vaccine and the levels of neutralizing antibody and IgG antibody against SARS-CoV-2.	From 14 days after the second dose to 1 year after the second dose.
Primary	The incidence of COVID-19 cases after two-doses of vaccination	The incidence of the symptomatic and laboratory-confirmed COVID-19 cases starting from Day 14 after the second dose.	From 14 days after the second dose to 1 year after the second dose.
Primary	The incidence of solicited AEs.	The incidence of solicited AEs at the inoculation site (local) and solicited AEs at the non-inoculation site (systemic) within 7 days after each dose	7 days after each dose
Secondary	The incidence of COVID-19 cases after at least one dose of immunization.	The incidence of the symptomatic and laboratory-confirmed COVID-19 cases after at least one dose of immunization.	From the first dose to 1 year after the second dose.
Secondary	The Geometric Mean Titer (GMT) of neutralizing antibody	The Geometric Mean Titer (GMT) of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The Geometric Mean Titer (GMT) of IgG antibody	The Geometric Mean Titer (GMT) of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The positive rates of neutralizing antibody	The positive rates of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The positive rates of IgG antibody	The positive rates of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The seroconversion rates of neutralizing antibody	The seroconversion rates of neutralizing antibody against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The seroconversion rates of IgG antibody	The seroconversion rates of IgG antibody (ELISA method) against SARS-CoV-2 14 days after the whole-course immunization.	14 days after the whole-course immunization
Secondary	The positive rates of neutralizing antibody	The positive rates of neutralizing antibody against SARS-CoV-2 6 months and 12 months after whole-course immunization.	6 months and 12 months after whole-course immunization.
Secondary	The positive rates of IgG antibody	The positive rates of IgG antibody (ELISA method) against SARS-CoV-2 6 months and 12 months after whole-course immunization.	6 months and 12 months after whole-course immunization.
Secondary	The Geometric Mean Titer (GMT) of neutralizing antibody	The Geometric Mean Titer (GMT) of neutralizing antibody against SARS-CoV-2 6 months and 12 months after whole-course immunization.	6 months and 12 months after whole-course immunization.
Secondary	The Geometric Mean Titer (GMT) of IgG antibody	The Geometric Mean Titer (GMT) of IgG antibody (ELISA method) against SARS-CoV-2 6 months and 12 months after whole-course immunization.	6 months and 12 months after whole-course immunization.
Secondary	Specific T cells with ELISPOT assay	Detecting specific T cells with ELISPOT assay 6 months and 12 months after the whole-course immunization	6 months and 12 months after the whole-course immunization
Secondary	The incidence of AEs	The incidence of AEs from the first dose to 28 days after whole-course immunization	From the first dose to 28 days after whole-course immunization.
Secondary	The incidence of SAEs	The incidence of SAEs from the first dose to at least 12 months after whole-course immunization.	From the first dose to at least 12 months after whole-course immunization.
Secondary	The occurrence of Antibody Dependent Enhancement (ADE)/ Vaccine Enhanced Disease(VED)	The occurrence of Antibody Dependent Enhancement (ADE)/ Vaccine Enhanced Disease(VED) that probably related to the laboratory-confirmed COVID-19 from 14 days after the second dose till the end of trial.	From 14 days after the second dose to 1 year after the second dose.